{"canonical":"https://abierto.us/vendors/venatorx-pharmaceuticals-inc-mbbknbu5dcc6","key":"MBBKNBU5DCC6","name":"VENATORX PHARMACEUTICALS INC","uei":"MBBKNBU5DCC6","city":"MALVERN","state":"PA","awards":6,"obligated":"40477463.94","notices_won":0,"top_agency_name":"Office of Assistant Secretary for Preparedness and Response","top_naics":"541714","cage":"61SY9","parent_name":"VENATORX PHARMACEUTICALS INC","also_known_as":[],"country":"USA","actions":31,"first_action":"2024-01-19","last_action":"2026-09-14","breakdowns":{"naics":[{"key":"541714","name":null,"awards":3,"obligated":"31255005.69"},{"key":"541715","name":null,"awards":1,"obligated":"9663737.75"},{"key":"541711","name":null,"awards":2,"obligated":"-441279.50"}],"places":[{"key":"PA","name":null,"awards":6,"obligated":"40477463.94"}],"agencies":[{"key":"7505","name":"Office of Assistant Secretary for Preparedness and Response","awards":3,"obligated":"31255005.69"},{"key":"7529","name":"National Institutes of Health","awards":2,"obligated":"9682675.64"},{"key":"9761","name":"Defense Threat Reduction Agency","awards":1,"obligated":"-460217.39"}],"award_types":[{"key":"DEFINITIVE CONTRACT","name":null,"awards":6,"obligated":"40477463.94"}],"competition":[{"key":"FULL AND OPEN COMPETITION","name":null,"awards":6,"obligated":"40477463.94"}],"product_service_codes":[{"key":"AN13","name":null,"awards":2,"obligated":"31255005.69"},{"key":"AN12","name":null,"awards":2,"obligated":"9682675.64"},{"key":"6505","name":null,"awards":1,"obligated":"0.00"},{"key":"AD92","name":null,"awards":1,"obligated":"-460217.39"}]},"awards_list":[{"award_key":"CONT_AWD_75A50123C00050_7505_-NONE-_-NONE-","permalink":"https://www.usaspending.gov/award/CONT_AWD_75A50123C00050_7505_-NONE-_-NONE-/","piid":"75A50123C00050","parent_piid":null,"award_type":"DEFINITIVE CONTRACT","vendor_key":"MBBKNBU5DCC6","recipient_name":"VENATORX PHARMACEUTICALS INC","recipient_uei":"MBBKNBU5DCC6","recipient_cage":"61SY9","recipient_city":"MALVERN","recipient_state":"PA","sub_name":"Office of Assistant Secretary for Preparedness and Response","office_name":"BARDA - ASPR / DAAPPO / BARDA DCMA","office_key":"o-75A501","first_action_date":"2024-01-31","last_action_date":"2026-08-04","actions":8,"obligated":"24870405.00","current_total_value":"45192122.00","potential_total_value":"191938367.00","naics":"541714","psc":"AN13","extent_competed":"FULL AND OPEN COMPETITION","set_aside":"NO SET ASIDE USED.","offers_received":1,"description":"THE PURPOSE OF THIS MODIFICATION IS TO UPDATE ARTICLE G.7 INDIRECT COST RATE","method":null,"confidence":null,"evidence":null,"opportunity_key":null,"opportunity_title":null},{"award_key":"CONT_AWD_75N93020C00016_7529_-NONE-_-NONE-","permalink":"https://www.usaspending.gov/award/CONT_AWD_75N93020C00016_7529_-NONE-_-NONE-/","piid":"75N93020C00016","parent_piid":null,"award_type":"DEFINITIVE CONTRACT","vendor_key":"MBBKNBU5DCC6","recipient_name":"VENATORX PHARMACEUTICALS INC","recipient_uei":"MBBKNBU5DCC6","recipient_cage":"61SY9","recipient_city":"MALVERN","recipient_state":"PA","sub_name":"National Institutes of Health","office_name":"NATIONAL INSTITUTES OF HEALTH NIAID","office_key":"o-75N930","first_action_date":"2024-07-01","last_action_date":"2026-09-14","actions":8,"obligated":"9663737.75","current_total_value":"25044892.75","potential_total_value":"44503613.75","naics":"541715","psc":"AN12","extent_competed":"FULL AND OPEN COMPETITION","set_aside":"NO SET ASIDE USED.","offers_received":12,"description":"NON BETA-LACTAM INHIBITORS OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII.","method":null,"confidence":null,"evidence":null,"opportunity_key":null,"opportunity_title":null},{"award_key":"CONT_AWD_75A50119C00007_7505_-NONE-_-NONE-","permalink":"https://www.usaspending.gov/award/CONT_AWD_75A50119C00007_7505_-NONE-_-NONE-/","piid":"75A50119C00007","parent_piid":null,"award_type":"DEFINITIVE CONTRACT","vendor_key":"MBBKNBU5DCC6","recipient_name":"VENATORX PHARMACEUTICALS INC","recipient_uei":"MBBKNBU5DCC6","recipient_cage":"61SY9","recipient_city":"MALVERN","recipient_state":"PA","sub_name":"Office of Assistant Secretary for Preparedness and Response","office_name":"BARDA - ASPR / DAAPPO / BARDA DCMA","office_key":"o-75A501","first_action_date":"2024-01-19","last_action_date":"2026-05-26","actions":9,"obligated":"6384600.69","current_total_value":"131756813.69","potential_total_value":"146866137.69","naics":"541714","psc":"AN13","extent_competed":"FULL AND OPEN COMPETITION","set_aside":"NO SET ASIDE USED.","offers_received":1,"description":"THE PURPOSE OF THIS MODIFICATION IS TO CORRECT THE PERIOD OF PERFORMANCE FOR CLIN0007 TO ALIGN WITH IPP.","method":null,"confidence":null,"evidence":null,"opportunity_key":null,"opportunity_title":null},{"award_key":"CONT_AWD_HHSN272201600029C_7529_-NONE-_-NONE-","permalink":"https://www.usaspending.gov/award/CONT_AWD_HHSN272201600029C_7529_-NONE-_-NONE-/","piid":"HHSN272201600029C","parent_piid":null,"award_type":"DEFINITIVE CONTRACT","vendor_key":"MBBKNBU5DCC6","recipient_name":"VENATORX PHARMACEUTICALS INC","recipient_uei":"MBBKNBU5DCC6","recipient_cage":"61SY9","recipient_city":"MALVERN","recipient_state":"PA","sub_name":"National Institutes of Health","office_name":"NATIONAL INSTITUTES OF HEALTH NIAID","office_key":"o-75N930","first_action_date":"2024-06-28","last_action_date":"2026-07-31","actions":6,"obligated":"18937.89","current_total_value":"48517078.64","potential_total_value":"48517078.64","naics":"541711","psc":"AN12","extent_competed":"FULL AND OPEN COMPETITION","set_aside":"NO SET ASIDE USED.","offers_received":13,"description":"THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP","method":null,"confidence":null,"evidence":null,"opportunity_key":null,"opportunity_title":null},{"award_key":"CONT_AWD_75A50122C00080_7505_-NONE-_-NONE-","permalink":"https://www.usaspending.gov/award/CONT_AWD_75A50122C00080_7505_-NONE-_-NONE-/","piid":"75A50122C00080","parent_piid":null,"award_type":"DEFINITIVE CONTRACT","vendor_key":"MBBKNBU5DCC6","recipient_name":"VENATORX PHARMACEUTICALS INC","recipient_uei":"MBBKNBU5DCC6","recipient_cage":"61SY9","recipient_city":"MALVERN","recipient_state":"PA","sub_name":"Office of Assistant Secretary for Preparedness and Response","office_name":"BARDA - ASPR / DAAPPO / BARDA DCMA","office_key":"o-75A501","first_action_date":"2024-01-24","last_action_date":"2026-05-13","actions":4,"obligated":"0","current_total_value":"72141707.00","potential_total_value":"318625321.00","naics":"541714","psc":"6505","extent_competed":"FULL AND OPEN COMPETITION","set_aside":"NO SET ASIDE USED.","offers_received":3,"description":"THE PURPOSE OF THIS MODIFICATION IS TO UPDATE ARTICLE G.12. INDIRECT COST RATE","method":null,"confidence":null,"evidence":null,"opportunity_key":null,"opportunity_title":null},{"award_key":"CONT_AWD_HDTRA117C0070_9700_-NONE-_-NONE-","permalink":"https://www.usaspending.gov/award/CONT_AWD_HDTRA117C0070_9700_-NONE-_-NONE-/","piid":"HDTRA117C0070","parent_piid":null,"award_type":"DEFINITIVE CONTRACT","vendor_key":"MBBKNBU5DCC6","recipient_name":"VENATORX PHARMACEUTICALS INC","recipient_uei":"MBBKNBU5DCC6","recipient_cage":"61SY9","recipient_city":"MALVERN","recipient_state":"PA","sub_name":"Defense Threat Reduction Agency","office_name":"DEFENSE THREAT REDUCTION AGENCY","office_key":"o-HDTRA1","first_action_date":"2026-02-17","last_action_date":"2026-04-30","actions":2,"obligated":"-460217.39","current_total_value":"14716732.53","potential_total_value":"19969099.47","naics":"541711","psc":"AD92","extent_competed":"FULL AND OPEN COMPETITION","set_aside":"NO SET ASIDE USED.","offers_received":3,"description":"NEW PBP INHIBITORS IMPERVIOUS TO BETA-LACTAMASES","method":null,"confidence":null,"evidence":null,"opportunity_key":null,"opportunity_title":null}],"awards_total":6,"awards_page":1,"won":[],"won_total":0,"solicitations_won":[]}